For patients where a stem cell therapy may not be an option, including older patients with ADA deficiency with partial ADA expression associated with late/adult onset, enzyme replacement by in vivo Ada gene delivery could provide an alternative therapeutic approach. This evidence concerns the gene ADA and hyperinsulinemic hypoglycemia, familial, 4.